Personal Genome Diagnostics (PGDx), a subsidiary of Laboratory Corporation of America Holdings, is at the forefront of closing the precision oncology gap. They provide revolutionary comprehensive genomic profiling solutions and services that empower patients and clinicians in the fight against cancer. PGDx offers a range of cutting-edge products under the brand name elio Solutions, including elio tissue complete, elio plasma complete, and elio plasma resolve.

These precision genomics kitted solutions enable personalized cancer care, empowering clinicians to make informed clinical decisions and researchers to conduct groundbreaking studies. In addition to their pioneering products, PGDx also provides Biopharma Services for both early-stage and late-stage drug development. By partnering with PGDx, biopharmaceutical companies gain access to proven thought leadership, regulatory expertise, and proprietary tools, accelerating their oncology drug development pipeline.

With a strong leadership team deeply rooted in genomics and a commitment to making precision oncology testing accessible for all, PGDx is revolutionizing the field of personalized medicine. Through their products, services, and dedication to patient care, they are making timely, personalized treatments a reality for patients worldwide. Stay connected with PGDx for the latest advancements in precision oncology